Avid Bioservices Inc (CDMO)

[nuke661]

Today's PR seems to have been an updated/revised version of the abstract release of Dr. Gupta's that was discussed on this board on 8-9-09 (see posts 39994 through 40002; especially 40001 posted by entdoc). My read on the differences is that today's info encompassed data results from 10 patients and the 8-9 data encompassed 8 patients. The most interesting thing that sticks out to me is that the progression free survival time and overall survival time for the 8-9 data (based on 8 patients) was 22 and 27 weeks respectively. These same data for today - based on 10 patients - were 33 and 41 weeks.

Seems to me to represent relatively significant improvement as time goes on. Could be even better considering that it appears the earlier survival times were weighted to the shorter side due to 2 deaths occurring very early in the trial. Realizing that the people going into the treatment are already experiencing recurrence and most likely are in late stage recurrence (considering the speed of this cancer and the time it takes to get into a trial) it appears to me that this drug has a much better potential than is being shown by the current survival data.

I'm not sure if I'm interpreting this data correctly because I see some confusing deltas between the 8-9 data and today's. For example the 8-9 report said follow ups ranged from 12-80 weeks and today's info stated a followup time range of 7 to 73 weeks. I don't know how the data points are adjusted for people who die or are removed from the study data.

This has to be the new standard of care soon, how can it not be!

I agree with those who are saying that this should be fast tracked and I certainly won't be surprised if some of the BIG NEWS in the near term is fast track approval. How can PPHM not already be pursuing fast track approval with the safety profile data and survival time results already in hand and the lack of treatments for this cancer. We MUST be near to fast track approval or there is something very wrong with our system.

ALL CONJECTURE OF COURSE.